

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Aflibercept for treating myopic choroidal neovascularisation

Batch 48

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the scoping consultation process, a consultee stated that myopic CNV was reported to be more common in people of Asian family origin.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population. No evidence was presented during consultation that suggested that aflibercept was less effective or had more safety issues in people of Asian family origin compared with other groups.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Yes. The background section of the scope has been updated to state that myopic CNV is reported to be more common in people of Asian family origin.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): ...Frances Sutcliffe.....

Date: 06/03/2017